Sustained suppression of ischemic complications of coronary intervention by platelet GpIIb/IIIa blockade with abciximab. One year outcome of the EPILOG trial - Lincoff,A.M.; Tcheng,J.E.; Califf,R.M.; for the EPILOG Investigators,null. (Circulation, 1999)